Related by context. All words. (Click for frequent words.) 66 Iluvien ® 65 generation proteasome inhibitor 64 topical anti infective 64 LUVENIQ 63 product platforms AZX# 63 tiapamil 63 generation purine nucleoside 63 ALN PCS 63 targeted radiotherapeutic 63 Archexin 63 Luveniq 62 molecular imaging radiopharmaceutical 62 Unit Dose Budesonide 62 Solazed TM 62 voclosporin 62 Personalized Immunotherapy 62 FOLOTYN ® 62 oncolytic virus therapies 62 Zemiva TM 62 oral prodrug 62 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 61 oral proteasome inhibitor 61 sumatriptan DosePro 61 Onalta ™ 61 MKC# MKC# PP 61 Inc. OTCBB MIVT 61 polymer platinate 61 mGluR5 negative 61 Besivance 61 bardoxolone 61 anti CD3 monoclonal 60 overactive bladder AA# 60 RhuDex ® 60 BEMA Buprenorphine 60 Shigamabs R 60 methylnaltrexone bromide 60 PNP inhibitor 60 treat male hypogonadism 60 Panzem R 60 romazarit 60 PDE4 inhibitor 60 platforms GVAX 60 Civacir 60 Frova ® 60 BCR ABL inhibitors 60 ZEFTERA TM Zevtera TM 60 LymphoStat B TM 60 Optiquel ™ 60 SYCREST 60 candidates Azedra 60 TRANSDUR ™ 60 label Lipofen R 60 investigational humanized monoclonal antibody 60 pralatrexate injection folate analogue 60 cancer immunotherapies 60 vaccines oncolytic virus 60 ocular formulation 59 Surfaxin LS 59 acyclovir Lauriad R 59 recombinant biopharmaceutical 59 ILUVIEN ® 59 Shigamabs ® 59 Prodarsan R 59 FWB MIV leading 59 Onalta 59 Bioral Amphotericin B 59 IMPACS R 59 Acetavance TM intravenous acetaminophen 59 POSIDUR TM ELADUR TM 59 XL# anticancer compounds 59 including eniluracil ADH 59 PGL# 59 CCR9 antagonist 59 oral nucleoside analogue 59 PrevOnco ™ 59 Rhucin ® recombinant 59 candidate REP# 59 volociximab 59 Daclizumab 59 ALN TTR# 59 vaginally administered lidocaine 59 mertansine 59 Zemiva ™ 59 VitiGam 59 IV APAP 59 Clevudine 59 leading oral taxane 59 acne impetigo 59 Tesetaxel 59 Silodosin 59 receptor tyrosine kinase inhibitor 59 inflammatory autoimmune diseases 59 histamine dihydrochloride 59 hypoxia activated prodrug 59 SCIB1 59 IND submission 59 Gentamicin Surgical Implant 59 PREOS R 59 SinuNase TM 59 Tezampanel 59 apricitabine ATC 59 generation URAT1 inhibitor 59 LymphoStat B belimumab 59 huC# DM4 59 NEBIDO R 58 MKC# MT 58 ionotropic glutamate receptor antagonists 58 IMA# 58 Loramyc R 58 rusalatide acetate 58 rheumatoid arthritis thrombocytopenia 58 Nektar PEGylation technology 58 Mipomersen 58 Angiocept 58 KNS # 58 novel L DOS# 58 IAP inhibitors 58 Nautilus Biotech 58 TRACON Pharmaceuticals Inc. 58 Solazed ™ 58 oral transdermal 58 ospemifene 58 Factor VIIa 58 DOS# 58 platinum chemotherapeutic 58 MT# MEDI 58 Zenvia ™ 58 omacetaxine mepesuccinate 58 pseudobulbar affect PBA 58 Loramyc TM 58 AzaSite Xtra 58 ZEVALIN ® 58 IL# PE#QQR 58 TKB# 58 5 HT3 antagonist 58 fipamezole 58 topical NSAID 58 HepeX B TM 58 Luramist TM 58 Peyronie disease Frozen Shoulder 58 HCV protease inhibitor 58 octreotide implant 58 seliciclib CYC# 58 GPR# agonist 58 Loramyc ™ 58 humanized anti 58 ELADUR ™ 58 non nucleoside inhibitor 58 Neo Urinary Conduit 58 Allovectin 7 58 acetonide FA 58 rALLy clinical trial 58 product candidate Lpathomab 58 Ozarelix 58 selective androgen receptor modulator 58 LEVADEX TM 58 oncology therapeutics 58 TRANSDUR Bupivacaine 58 delivery polymer matrix 58 LEVADEX ™ 58 Myocet 58 TRANSDUR Sufentanil 58 drug ISA# 58 patented Bioral 58 Dyloject TM 58 dasatinib Sprycel ® 58 P#X# antagonist 58 Allovectin 7 R 58 multi kinase inhibitor 58 LHRH antagonist 58 virus HCV protease inhibitor 58 generation biocompatible coatings 58 Elagolix 58 TBC# 58 sterile lidocaine patch 58 Phase 2b clinical trials 58 Phase Ib study 58 Cloretazine ® 58 Pirfenidone 58 REMOXY ® 58 AAG geldanamycin analog 57 unique alkylating agent 57 DosePro TM 57 Proxinium TM 57 phase IIb clinical 57 Exherin TM 57 candidates bavituximab 57 Loramyc ® 57 RELISTOR ® 57 ALN TTR 57 AcryMed Incorporated 57 Targeted Chemotherapy 57 novel antibody therapeutics 57 topical dermatology 57 MAP# 57 Exelixis compounds 57 Omigard TM 57 Pimavanserin 57 Ophthotech 57 Phase IIb trials 57 isoform selective 57 Nexavar ® 57 diarrhea predominant irritable 57 valtorcitabine 57 BENLYSTA ® 57 candidate Zenvia 57 RECOTHROM R 57 Zensana TM 57 Annamycin 57 nalbuphine ER 57 Azedra TM Onalta TM 57 Plasma Converter TM 57 CD# CEA 57 Prednisporin 57 herpetic keratitis 57 subcutaneous formulation 57 motexafin gadolinium Injection 57 luliconazole 57 anti infective treatments 57 Nasdaq HALO biopharmaceutical 57 ATryn ® 57 Tostrex 57 Soliris TM eculizumab 57 REMOXY POSIDUR ELADUR 57 ELADUR TM 57 HuMax TAC 57 AEG# 57 Receives Orphan Drug Designation 57 Drug Eluting Stent System 57 XL# XL# 57 oral taxane 57 generation NNRTI 57 OvaRex ® MAb 57 candidate AQ4N 57 polymerase inhibitor 57 torezolid phosphate 57 Lipid Polymer Micelle LPM 57 ALTROPANE R 57 Thrombin topical Recombinant 57 Urokinase 57 anticancer compound 57 R DepoCyt 57 liposomal formulation 57 Vascular Wrap TM 57 ATL# [001] 57 Prodarsan ® 57 Epeius Biotechnologies Corporation 57 Zingo TM 57 Indaflex TM 57 sodium thiosulfate STS 57 TELINTRA 57 TYZEKA 57 Ketotransdel 57 JAK1 57 Emezine 57 BEMA Granisetron 57 candidate Zemiva TM 57 XmAb ® 57 muscarinic receptor agonists 57 Oracea TM 57 PDX pralatrexate 57 oncolytic vaccine 57 histone deacetylase HDAC inhibitor 57 buccal insulin spray 57 Relivar 56 XP# XP# 56 topically delivered 56 MBP# [001] 56 Nutra Pharma wholly owned 56 phase IIa clinical 56 Cetrorelix 56 Zelrix 56 Onco TCS 56 PrevOnco 56 dextromethorphan quinidine 56 QNEXA ® 56 MOVIPREP R 56 talactoferrin 56 FACTIVE R gemifloxacin 56 Fodosine 56 Ceflatonin R 56 patented Bioral R nanocochleate 56 drug pipeline TAFA# 56 lexidronam injection 56 antisense drug 56 peripherally acting 56 Onalta TM 56 Currently RegeneRx 56 JAK inhibitor 56 registrational trial 56 delta opioid receptor 56 Polymer Microspheres 56 Fx #A 56 commercialize AzaSite 56 MAA submission 56 Curaxin 56 investigational pan BCR 56 Initiates Clinical Trial 56 R#/MEM 56 PORxin TM platforms 56 trastuzumab DM1 T DM1 56 QRxPharma 56 nucleoside polymerase inhibitor 56 CRMD# 56 Preotact 56 proven DuraSite ® 56 SPL# Gel vaginal microbicide 56 Loramyc 56 ISENTRESS raltegravir 56 dirucotide 56 Bioral ® 56 topically applied SEPA 56 Abstral ® 56 OvaRex R 56 telomerase therapeutic 56 Ecallantide 56 Commence Phase 56 Circ Pharma 56 Dapagliflozin 56 BENLYSTA ™ 56 LUCASSIN 56 vascular disrupting agent 56 CytoFab 56 KALBITOR ® 56 NICOSAN TM 56 BEMA TM Fentanyl 56 AzaSite Plus 56 injectable formulation 56 PHX# 56 GENTAMICIN SURGICAL IMPLANT 56 ketolide antibiotic 56 ozarelix 56 OncoVEX GM CSF 56 Crofelemer 56 Vitamin D analogue 56 Captisol ® 56 humanized monoclonal antibody 56 Ostabolin C TM 56 NP2 Enkephalin 56 candidate deforolimus 56 incyclinide 56 Qutenza TM 56 antibody MAb 56 novel orally administered 56 Opterone R 56 BCX# 56 Augment TM 56 CB2 selective receptor agonist 56 Initiate Phase 56 selective androgen receptor modulators 56 First Patient Dosed 56 Completes Patient Enrollment 56 Solasia 56 SUMAVEL 56 Hepatitis C HCV 56 pafuramidine maleate 56 Cellegesic 56 oral ridaforolimus 56 Azedra 56 CEQ# 56 % uracil topical 56 Prednisporin TM 56 oxybutynin ATD TM 56 Pliaglis 56 IIa clinical trials 56 THR beta agonist 56 PEGylated interferon 56 inhaled formulation 56 Safinamide 56 serine protease inhibitor CU# 56 Phase #b/#a clinical 56 Pivotal Phase III 56 Cutanea Life Sciences 56 JOULFERON 56 prostone 56 Levulan PDT 56 CORT # 56 ularitide 56 glucokinase activator 56 Ferring Pharmaceuticals specializes 56 Pennsaid Plus 56 Rotarix R 56 GALNS 56 investigational antiplatelet agent 56 ITAX 56 Iluvien TM 56 Cintredekin Besudotox 55 #D#C# 55 Phase IIb Trial 55 subsidiaries visit http:/www.apricusbio.com 55 DPP4 inhibitor 55 Aganocide ® 55 Phase IIa trials 55 Aerosurf 55 ATG Fresenius S 55 ophthalmic diseases 55 GTC recombinant human 55 MT#/MEDI-# 55 KRYSTEXXA TM pegloticase 55 NuroPro 55 MAXY alpha 55 Perflubutane Polymer Microspheres 55 Oncaspar 55 MKC# 55 DR Cysteamine 55 Ganciclovir 55 Aurora kinase inhibitor 55 clinical trials Archexin 55 ONSOLIS TM 55 OncoGel 55 Phase IIb clinical trials 55 Chimigen 55 lucinactant 55 Urocidin 55 Initiates Enrollment 55 SNT MC# 55 IAP inhibitor 55 RenaZorb TM 55 tamibarotene 55 non nucleoside HCV 55 Bicifadine 55 Tesamorelin 55 zolpidem tartrate sublingual tablet 55 Phase 1b clinical trials 55 therapeutic monoclonal antibody 55 PANVAC VF 55 SinuNase ™ 55 IgG1 monoclonal antibody 55 tezampanel 55 Novosom 55 lead molecular radiotherapeutic 55 Bioral Amphotericin B. 55 Icatibant 55 AcryMed technologies 55 Zerenex 55 novel histone deacetylase 55 Prochymal TM 55 VEGFR2 inhibitor 55 Files IND 55 Orapred ODT 55 miconazole Lauriad 55 DB# [003] 55 deforolimus 55 compound PMX # 55 utilizes InSite Vision 55 palifosfamide Zymafos TM 55 Ophena TM 55 lintuzumab SGN 55 Simulect 55 ATL/TV# 55 Aflibercept 55 proteasome inhibitor 55 dermatology biopharmaceutical 55 IND Investigational New 55 outlicensed 55 buccal soluble film 55 TASKi2 55 Cobalamin 55 Initiates Phase II 55 EyeGate 55 Zemiva TM Trofex TM 55 Allovectin 7 r 55 rxRNA 55 Application BLA 55 includes TOLAMBA TM 55 IND enabling 55 SARMs 55 Aztreonam 55 mitogen activated ERK kinase 55 Preotact R 55 renin inhibition promising 55 Panzem R NCD 55 Omigard 55 anticancer agent 55 human C1 inhibitor 55 ProEthic Pharmaceuticals 55 afamelanotide 55 Chemokine Therapeutics 55 Alocrest 55 DDP# 55 RECOTHROM ® 55 NVA# 55 therapeutic monoclonal antibodies 55 MONOVISC 55 Liposomal 55 intranasal formulation 55 PI3K/Akt pathway inhibitor 55 Omacetaxine 55 Anturol TM 55 Valtropin 55 Phase #b/#a trial 55 Generx TM 55 Phase 2b Clinical Trial 55 NYSE Amex NBY clinical 55 Voclosporin 55 phase IIb 55 PEG SN# 55 GLP1 INT TM 55 Therapeutic Vaccine 55 fluorinated carbohydrate mimics 55 TAFA# 55 Eligard R 55 antibody MT# 55 AeroLEF R 55 Ferumoxytol 55 Nanobody R 55 YONDELIS R 55 Vicinium TM 55 severe gastroparesis 55 OTC BB PVCT 55 ZaBeCor 55 Lovaza TM 55 CCR5 antagonist 55 PRT# 55 Rescula 55 candidate Puricase 55 GEM #S 55 LEP ETU 55 oral anticancer 55 Ofatumumab 55 Amrubicin 55 Diamyd R 55 ARIKACE ™ 55 candidate epratuzumab 55 investigational compound 55 Lupuzor 55 eSensor detection technology 55 NICOSAN ™ 55 EpiCeram 55 product Abreva ® 55 T Pred 55 Phase Ib clinical trials 55 Ruconest 55 forodesine hydrochloride 55 Albugon 55 NGX# 55 transdermal spray 55 Phase 2b clinical 55 dermatology therapies 55 R PEG uricase 55 ForSight Newco II 55 DPX Survivac 55 commercialize dutogliptin 55 SAR# [002] 55 drug GAP #B# 55 R Abelcet 55 Cobalamin TM mediated 55 ALN HPN 55 Phase IIa trial 55 BrachySil 55 SmartChip TM 55 Pazopanib 55 highly selective inhibitor 55 Sanvar R 55 CDP# 55 Iloperidone 55 Behcet uveitis 55 SUCCEED trial 55 zanolimumab 55 Hematide ™ 55 NEBIDO 55 renin inhibitor 55 BiTE R 55 Actemra tocilizumab 55 IGN# 55 Kosan dependence 54 Topical Interferon Alpha 2b 54 highly selective adenosine 54 ARRY # 54 Ciclesonide 54 Soliris eculizumab 54 POSIDUR ™ 54 highly purified pasteurized 54 OTCQX QRXPY 54 GATTEX TM 54 Vicriviroc 54 Phase III clinical trials 54 Alvesco R 54 HGS# 54 treat refractory angina 54 commercialize Aganocides 54 Tarceva TM 54 generation NEUGENE antisense 54 Spiegelmer ® 54 Femprox ® 54 Valortim TM 54 Initiates Clinical 54 ASONEP 54 DIFICID ™ 54 delivers sumatriptan 54 docetaxel Taxotere R 54 EVIZON ™ 54 ABL inhibitor 54 aerosolized AAT 54 AKT inhibitor 54 OMNARIS HFA 54 Phase III Pivotal 54 Evoltra TM 54 proprietary transdermal patch 54 NASDAQ BTRX pharmaceutical 54 crofelemer 54 TRANSDUR TM Sufentanil 54 immunotherapeutic vaccine 54 Nanobody ® 54 aesthetic dermatology 54 docosanol 54 elotuzumab 54 XL# XL# XL# 54 MVA HPV IL2 54 Affilin ® 54 Nimotuzumab 54 liver resection surgeries 54 Anavex #-# 54 include Phenoptin TM 54 Dalbavancin 54 Syncria 54 candidate Zemiva 54 ImmuneRegen BioSciences Inc. 54 Syntonix 54 epothilone 54 ThermoDox R 54 product platforms GVAX 54 Orphan Drug designation 54 REMOXY R 54 TFChem licenses 54 PSN# [002] 54 Aganocide 54 Marketing Authorisation Application 54 RONDEL ™ 54 Anidulafungin 54 therapeutic peptide 54 CONBRIZA 54 Ceplene TM 54 Ceragenin ™ 54 anti botulism antibody 54 Meets Primary Endpoint 54 Miraxion Amarin lead 54 OLpur TM H2H 54 beta 1a 54 Xcytrin R 54 R#/MEM # 54 products Oncaspar ® 54 EGRIFTA TM 54 anti TNF alpha 54 Phase III clinical 54 PROGENSA R 54 Generx ™ 54 intranasal vaccines derived 54 forodesine 54 Locked Nucleic Acid 54 Tyrima 54 ATL# [002] 54 Ceflatonin 54 EpiCeram ® 54 Orphan Drug designations 54 commercializing anti infective 54 diabetes irritable bowel 54 Selective Electrochemical Tumor Ablation 54 JZP 54 Phase IIa clinical trials 54 HepeX B 54 LEUKINE 54 Dacogen injection 54 BLP# Liposome Vaccine 54 LE SN# 54 Phase III Clinical Trial 54 Troxatyl 54 phase IIb trial 54 immunotherapeutics 54 Fc fusion protein 54 Phase 2a clinical 54 EndoTAG TM 54 Atiprimod 54 ASONEP TM 54 Evamist TM 54 Taiho Pharmaceutical 54 Golimumab 54 phase IIb III 54 Gemin X 54 FDA Accepts 54 drugs alitretinoin ceftobiprole 54 XL# XL# XL# XL# 54 TELINTRA R 54 selectin antagonist 54 immatics 54 Cara Therapeutics 54 BLA filing 54 Xcellerex FlexFactory 54 DermaVir Patch 54 Hedgehog antagonist 54 candidate WF# 54 TLK# 54 Granted Orphan Drug 54 candidates Dyloject TM 54 romidepsin novel 54 InNexus Biotechnology 54 HuMax CD4 54 ENTEREG ® 54 Company patented BEMA 54 Oral NKTR 54 anticancer compounds 54 NuMimetic TM 54 Glassia 54 GlycoPEG GCSF 54 Fentanyl TAIFUN R 54 Symphony tCGM System 54 Phase 2b 54 Expression Genetics 54 Initiates Phase 54 EGS# 54 CDAD Clostridium difficile 54 Initiate Clinical Trial 54 Testosterone MDTS ® 54 Lenocta TM 54 BioNeutral antimicrobial formulations 54 candidate Zelrix 54 Dicer Substrate Technology 54 generation rotary VAD 54 VIVITROL ® 54 PROSTASCINT R 54 Phenomix Corporation 54 Naproxcinod 54 Virulizin R 54 HepaGam B R 54 Celsion Corporation 54 Octreotide 54 ZFP Therapeutics 54 intranasal insulin product 54 Phase Ib 54 biased ligand 54 TRX1 54 Evoltra ® 54 OTCBB QTXB 54 autoimmune indications 54 successfully commercialize Iluvien 54 PN# [001] 54 commercialization 54 adrenergic regulation 54 non personalized allogeneic 54 StromaCel 54 R roscovitine CDK cyclin 54 E1 INT TM 54 EVIZON TM 54 #L Sterilizer 54 R roscovitine 54 Drug Candidate 54 Completes Enrollment 54 intravenous formulation 54 Orphan Drug status 54 Homspera TM 54 BioMimetic seeks 54 Junovan TM 54 OHR/AVR# 54 miconazole Lauriad ® 54 Patient Enrolment 54 Traficet EN 54 dependent kinase inhibitor 53 NTDDS 53 RNAi therapeutic targeting 53 immunosuppressive compound 53 KRN# 53 Adenosine Therapeutics 53 relapsed refractory multiple myeloma 53 Celator 53 EHT AGN 53 Firdapse 53 Belinostat 53 Intermezzo ® zolpidem tartrate 53 developing TB4 53 relapsed leukemia 53 Phase 2a clinical trials 53 BRILINTA 53 UltiMAb ® 53 novel oral anticoagulant 53 EpiCeram R 53 PLK1 SNALP 53 Pharmos pipeline 53 Lymphoseek ® 53 Commences Phase 53 Sapacitabine 53 Romidepsin 53 initiate Phase IIb 53 IRX 2 53 Shigamabs 53 Provectus Pharmaceuticals specializes 53 Urocidin TM 53 registrational 53 PROVENGE sipuleucel T 53 Micromet BiTE 53 INS# [001] 53 Teflaro 53 vidofludimus 53 fusion inhibitor 53 GLP toxicology studies 53 EndoTAG TM -1 53 Friedreich Ataxia FRDA 53 ImmunoGen TAP technology 53 Novolimus 53 DURIN TM 53 SUTENT ® 53 AlphaRx 53 DURIN 53 Locked Nucleic Acid LNA 53 Perifosine 53 New Chemical Entities 53 PROMACTA ® 53 MEK inhibitor 53 SansRosa 53 PharmFilm ® 53 ATryn R 53 DermTech International 53 commercializing therapeutic 53 LUNESTA TM 53 OXi# 53 Syncria albiglutide 53 Phase IIa clinical 53 Anturol ® 53 HCD# [002] 53 SILENOR 53 Atrigel 53 CR# vcMMAE 53 Zenpep 53 outlicensing 53 Ridaforolimus 53 Pafuramidine 53 Phase 2a Trial 53 Phase III pivotal 53 MOZOBIL 53 ONCONASE R 53 RNA interference RNAi therapeutics 53 NYSE Amex PBTH 53 ZFNs clinical trials 53 Exocrine Pancreatic Insufficiency 53 Genaera Corporation 53 investigational drug 53 Solazed 53 Neo Kidney Augment 53 pivotal Phase III 53 Marketing Authorization Application MAA 53 Captisol enabled 53 initiated Phase Ib 53 aurora kinase 53 Litx 53 photodisinfection 53 Testosterone MDTS R 53 transmucosal delivery system 53 Somatuline Depot 53 Cx# [002] 53 Bioral 53 Phase 2a Clinical Trial 53 nitric oxide donating 53 Corlux 53 intravenous AAT 53 oral NKTR 53 HIV integrase inhibitor 53 UPLYSO 53 Intarcia 53 Voraxaze 53 Ampligen R 53 CTA# Injection 53 L BLP# 53 Clofarabine 53 SGLT Inhibitors 53 alvespimycin 53 commercialize Aganocide compounds 53 REGiMMUNE 53 Flutiform TM 53 Qnexa TM 53 3 registrational trial 53 HepDirect R 53 Immunotherapeutic 53 INTERCEPT red 53 Celacade TM 53 novel immunotherapies 53 INOmax R 53 Phase Ib II 53 Patient Enrollment 53 INTELLITAB TM 53 IIa trial 53 Phase III Clinical Trials 53 UltiMAb 53 Orphan Drug Status 53 sulodexide 53 Avila Therapeutics 53 OTCBB PYTO 53 topical formulation 53 EpiCept NP 1 53 OPTTX System 53 Cleviprex TM clevidipine 53 Recombinant Human 53 opioid induced bowel dysfunction 53 CRF1 receptor antagonist 53 Symphony tCGM 53 ruxolitinib 53 Apaziquone 53 Hematide ™ peginesatide 53 Vaccinex 53 novel peptides 53 Apo AIMilano 53 SNALP technology 53 gastro intestinal inflammation 53 TOCOSOL 53 Pruvel 53 Completes Patient Enrolment 53 Phase Ib IIa 53 confirmatory Phase III 53 NUEDEXTA ™ 53 faropenem medoxomil 53 confirmatory Phase 3 53 trodusquemine MSI 53 oral probiotic 53 BEMA Fentanyl 53 INCB# [002] 53 triciribine phosphate monohydrate 53 Uracyst 53 Marketing Authorization Application 53 Hsp# Inhibitor 53 drug conjugate 53 investigational HCV polymerase 53 Lipocine 53 Kyowa Kirin 53 Medidur TM FA 53 phase IIa 53 Pivotal Phase 53 Saforis 53 SARcode 53 phase Ib clinical 53 Fentanyl Taifun 53 LentiVector technology 53 Helsinn Healthcare 53 miconazole Lauriad R 53 Albuferon albinterferon alfa 2b 53 Alzhemed TM 53 Rhucin ® 53 orally administered inhibitor 53 Ustekinumab 53 Aviptadil 53 Pennsaid R 53 vinorelbine emulsion 53 Phase 1b clinical 53 RhuDex TM 53 NADiA ProsVue 53 mild vasodilator 53 Indaflex 53 BLA submission 53 Japanese Encephalitis vaccine 53 EVIZON TM squalamine lactate 53 Tyzeka Sebivo 53 Glatiramer Acetate 53 ATD Gel 53 Firazyr ® 53 EDEMA3 53 Cannabinor 53 Uvidem 53 Oral Calcitonin 53 Files Investigational 53 treat dysmenorrhea 53 Rotarix ® 53 Tamibarotene 53 OMAPRO ™ 53 Oasmia 53 Alfacell proprietary ribonuclease 53 TKM ApoB 53 Microplasmin 53 Degarelix 53 VivaGel TM 52 PSN# [001] 52 cannabinor 52 Firazyr 52 Initiated Phase 52 candidates budesonide MMX 52 Lauriad 52 Marketing Authorization Applications 52 NeoVisc R 52 Tranzyme Pharma 52 diabetic neuropathic pain 52 OXIGON 52 Biopartners 52 multicenter Phase III 52 IMC #B 52 SEPET TM 52 Marqibo 52 oral antiviral 52 Inc. AMEX LIV 52 Eligard ® 52 Onconase 52 Virulizin 52 TP# CETi 1 52 oral formulation 52 Adnectin 52 Somatuline R Autogel R 52 Teysuno 52 Submits NDA 52 Bukwang Pharmaceuticals 52 commercialize telaprevir 52 Cutanea 52 Ampligen ® 52 Curaxin CBLC# 52 Quinamed